Physician profile
David Panossian
NPI 1366504532
$822.28
in general payments reported to CMS, 2019-2025
10 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2021: $30.95 · 2022: $205 · 2023: $36.81 · 2024: $134 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $228 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.13 |
| Education | $188.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $189.30 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.83 | 2019-2025 | Jascayd |
| Sanofi-Aventis U.S. LLC | $171.98 | 2025 | |
| Jazz Pharmaceuticals INC. | $138.06 | 2022 | |
| United Therapeutics Corporation | $34.41 | 2022-2023 | Tyvaso |
| Insmed, INC. | $32.48 | 2022-2024 | Arikayce |
| Genentech USA, INC. | $29.50 | 2019 | |
| Gilead Sciences, INC. | $18.90 | 2022 | |
| Inspire Medical Systems, INC. | $18.11 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $16.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Panossian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.